Next Article in Journal
Genetic and Drug Inhibition of LDH-A: Effects on Murine Gliomas
Next Article in Special Issue
Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma
Previous Article in Journal
MEOX2 Regulates the Growth and Survival of Glioblastoma Stem Cells by Modulating Genes of the Glycolytic Pathway and Response to Hypoxia
Previous Article in Special Issue
A Prognostic Model Using Post-Steroid Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Primary Central Nervous System Lymphoma
 
 
Article

Circulating microRNAs in Cerebrospinal Fluid and Plasma: Sensitive Tool for Detection of Secondary CNS Involvement, Monitoring of Therapy and Prediction of CNS Relapse in Aggressive B-NHL Lymphomas

1
Institute of Pathological Physiology, 1st Faculty of Medicine, Charles University, 128 53 Prague, Czech Republic
2
Department of Haematology, University Hospital Kralovske Vinohrady and 3rd Faculty of Medicine, Charles University, 100 34 Prague, Czech Republic
3
1st Department of Medicine, Charles University General Hospital, 128 08 Prague, Czech Republic
4
Faculty of Mathematics and Physics, Charles University, 186 75 Prague, Czech Republic
5
Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, St James’s University Hospital, University of Leeds, Leeds LS2 9JT, UK
6
Department of Cell Therapy, Institute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic
7
Biocev, 1st Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editors: Pier Luigi Zinzani and Paul Murray
Cancers 2022, 14(9), 2305; https://doi.org/10.3390/cancers14092305
Received: 15 March 2022 / Accepted: 7 April 2022 / Published: 6 May 2022
(This article belongs to the Special Issue Non-Hodgkin Lymphomas)
Lymphoma involving the central nervous system and CNS relapse present diagnostic and predictive challenges. Its diagnosis is based on conventional methods with low sensitivity and/or specificity. More powerful tools for its early detection, response evaluation, and CNS relapse prediction are needed. MicroRNAs are short post-transcriptional gene regulators that are remarkably stable and detectable extracellularly in body fluids. We evaluated the diagnostic and predictive potential of circulating oncogenic microRNAs (oncomiRs) in CSF and plasma for the detection of secondary CNS involvement in aggressive B-NHL lymphomas, as well as for detection and prediction of their CNS relapse. Our findings indicate that the evaluation of oncogenic microRNAs in CSF and plasma potentially provides a sensitive tool for the early detection of secondary CNS lymphoma, the monitoring and estimating of treatment efficacy, and the prediction and early detection of CNS relapse.
Lymphoma with secondary central nervous system (CNS) involvement represents one of the most aggressive malignancies, with poor prognosis and high mortality. New diagnostic tools for its early detection, response evaluation, and CNS relapse prediction are needed. We analyzed circulating microRNAs in the cerebrospinal fluid (CSF) and plasma of 162 patients with aggressive B-cell non-Hodgkin’s lymphomas (B-NHL) and compared their levels in CNS-involving lymphomas versus in systemic lymphomas, at diagnosis and during treatment and CNS relapse. We identified a set of five oncogenic microRNAs (miR-19a, miR-20a, miR-21, miR-92a, and miR-155) in CSF that detect, with high sensitivity, secondary CNS lymphoma involvement in aggressive B-NHL, including DLBCL, MCL, and Burkitt lymphoma. Their combination into an oncomiR index enables the separation of CNS lymphomas from systemic lymphomas or nonmalignant controls with high sensitivity and specificity, and high Receiver Operating Characteristics (DLBCL AUC = 0.96, MCL = 0.93, BL = 1.0). Longitudinal analysis showed that oncomiR levels reflect treatment efficacy and clinical outcomes, allowing their monitoring and prediction. In contrast to conventional methods, CSF oncomiRs enable detection of early and residual CNS involvement, as well as parenchymal involvement. These circulating oncomiRs increase 1–4 months before CNS relapse, allowing its early detection and improving the prediction of CNS relapse risk in DLBCL. Similar effects were detectable, to a lesser extent, in plasma. View Full-Text
Keywords: CNS; lymphoma; microRNA; DLBCL; MCL; Burkitt; B-NHL; relapse; cerebrospinal fluid; plasma CNS; lymphoma; microRNA; DLBCL; MCL; Burkitt; B-NHL; relapse; cerebrospinal fluid; plasma
Show Figures

Figure 1

MDPI and ACS Style

Krsmanovic, P.; Mocikova, H.; Chramostova, K.; Klanova, M.; Trnkova, M.; Pesta, M.; Laslo, P.; Pytlik, R.; Stopka, T.; Trneny, M.; Pospisil, V. Circulating microRNAs in Cerebrospinal Fluid and Plasma: Sensitive Tool for Detection of Secondary CNS Involvement, Monitoring of Therapy and Prediction of CNS Relapse in Aggressive B-NHL Lymphomas. Cancers 2022, 14, 2305. https://doi.org/10.3390/cancers14092305

AMA Style

Krsmanovic P, Mocikova H, Chramostova K, Klanova M, Trnkova M, Pesta M, Laslo P, Pytlik R, Stopka T, Trneny M, Pospisil V. Circulating microRNAs in Cerebrospinal Fluid and Plasma: Sensitive Tool for Detection of Secondary CNS Involvement, Monitoring of Therapy and Prediction of CNS Relapse in Aggressive B-NHL Lymphomas. Cancers. 2022; 14(9):2305. https://doi.org/10.3390/cancers14092305

Chicago/Turabian Style

Krsmanovic, Pavle, Heidi Mocikova, Kamila Chramostova, Magdalena Klanova, Marie Trnkova, Michal Pesta, Peter Laslo, Robert Pytlik, Tomas Stopka, Marek Trneny, and Vit Pospisil. 2022. "Circulating microRNAs in Cerebrospinal Fluid and Plasma: Sensitive Tool for Detection of Secondary CNS Involvement, Monitoring of Therapy and Prediction of CNS Relapse in Aggressive B-NHL Lymphomas" Cancers 14, no. 9: 2305. https://doi.org/10.3390/cancers14092305

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop